{"title": "PDF", "author": "PDF", "url": "s3.amazonaws.com/cdn.smfm.org/media/3234/Covid_Vaccine_Reasons.Spanish.2.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "\u00bfEst\u00e1 embarazada? \u00bfEst\u00e1 pensando en quedar  \nembarazada? \u00bfHa estado embarazada recientemente?   \nLas 5 razones principales para vacunarse contra  \nel COVID-19\n    Las vacunas contra el COVID-19 no tienen ning\u00fan efecto sobre la  \n   fertilidad. No hay informaci\u00f3n que sugiera que alguna vacuna, incluidas \nlasvacunas contra el COVID-19, afecte su capacidad para quedar  \nembarazada ahora o en el futuro 9, 21-23.\n    Las personas embarazadas pueden presentar los mismos efectos secundarios leves  \n   de las vacunas contra el COVID-19, como fiebre, dolor de cabeza y cansancio, que las \npersonas no embarazadas. Las personas embarazadas que han sido vacunadas no han \ninformado efectos secundarios graves 9, 24, 25.\u277a    Los anticuerpos que su cuerpo produce en respuesta a la vacuna    \n   pueden atravesar la placenta y llegar a su beb\u00e9 10, 11. La lactancia tambi\u00e9n \ntransfiere anticuerpos a su beb\u00e9 12-14. Los anticuerpos de la vacuna pueden \nayudar a proteger a su beb\u00e9 contra el COVID-19 despu\u00e9s del nacimiento 15.\n    Miles de personas embarazadas han recibido vacunas contra el COVID-19 deforma  \n   segura. No ha habido informes de un mayor riesgo de p\u00e9rdida del embarazo 16-20,  \nproblemas de crecimiento del feto o defectos de nacimiento 9.\u2778    Las personas embarazadas tienen m\u00e1s probabilidades de enfermarse gravemente  \n   por COVID-19 que las personas no embarazadas 1-4. Contraer COVID-19 durante el \nembarazo aumenta el riesgo de parto prematuro 5 y el riesgo de que su beb\u00e9 necesite \ncuidados intensivos 6. Recibir la vacuna ayuda a protegerlos a usted y a su beb\u00e9 de  \nenfermar gravemente, ser hospitalizados y morir por COVID-19 7-9.1\n\u2776\nConozca los datos. \nVac\u00fanese.\nEscanee para ver una versi\u00f3n web \ncon enlaces a las referencias.\nThis infographic was supported by the American College of Obstetricians and Gynecologists (ACOG) and the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as a part of a financial assistance  \naward totaling $15,000 with 100 percent funded by ACOG and CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by ACOG, CDC/HHS, or the U.S. Government.Referencias\n1. Ellington S, Strid P, Tong VT, Woodworth K, Galang RR, Zambrano LD, et al. Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-June 7, 2020. MMWR Morbidity and \nmortality weekly report. 26 de junio de 2020; 69(25):769-75.\n2. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020. \nMWR Morbidity and mortality weekly report. 6 de noviembre de 2020; 69(44):1641-7.\n3. Panagiotakopoulos L, Myers TR, Gee J, Lipkind HS, Kharbanda EO, Ryan DS, et al. SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics - Eight U.S. Health Care Centers, March 1-May 30, 2020. \nMMWR Morbidity and mortality weekly report. 23 de septiembre de 2020; 69(38):1355-9.\n4. Delahoy MJ, Whitaker M, O\u2019Halloran A, Chai SJ, Kirley PD, Alden N, et al. Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 - COVID-NET, 13 States, March 1-August 22, 2020. MMWR \nMorbidity and mortality weekly report. 25 de septiembre de 2020; 69(38):1347-54.\n5. Karasek D, Baer RJ, McLemore MR, Bell AJ, Blebu BE, Casey JA, et al. The association of COVID-19 infection in pregnancy with preterm birth: A retrospective cohort study in California. Lancet Reg Health Am. Octubre de 2021; 2:100027.\n6. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis.\n7. Dagan N, Barda N, Biron-Shental T, Makov-Assif M, Key C, Kohane IS, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med. Octubre de 2021; 27(10):1693-5.\n8. Goldshtein I, Nevo D, Steinberg DM, Rotem RS, Gorfine M, Chodick G, et al. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women. Jama. 24 de agosto de 2021; 326(8):728-35.\n9. Girardi G, Bremer AA. Scientific Evidence Supporting Coronavirus Disease 2019 (COVID-19) Vaccine Efficacy and Safety in People Planning to Conceive or Who Are Pregnant or Lactating. Obstet Gynecol. 2 de noviembre de 2021.\n10. Beharier O, Plitman Mayo R, Raz T, Nahum Sacks K, Schreiber L, Suissa-Cohen Y, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. J Clin Invest. 1 de octubre de 2021; 131(19).\n11. Prabhu M, Murphy EA, Sukhu AC, Yee J, Singh S, Eng D, et al. Antibody Response to Coronavirus Disease 2019 (COVID-19) Messenger RNA Vaccination in Pregnant Women and Transplacental Passage Into Cord Blood. Obstet Gynecol. 1 de agosto de 2021; 138(2):278-80.\n12. Perl SH, Uzan-Yulzari A, Klainer H, Asiskovich L, Youngster M, Rinott E, et al. SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women. Jama. 18 de mayo de 2021; 325(19):2013-4.\n13. Pace RM, Williams JE, Jarvinen KM, Belfort MB, Pace CDW, Lackey KA, et al. Characterization of SARS-CoV-2 RNA, Antibodies, and Neutralizing Capacity in Milk Produced by Women with COVID-19. mBio. 9 de febrero de 2021; 12(1). pubmed/33563823.\n14. Romero Ramirez DS, Lara Perez MM, Carretero Perez M, Suarez Hernandez MI, Martin Pulido S, Pera Villacampa L, et al. SARS-CoV-2 Antibodies in Breast Milk After Vaccination. Pediatrics. Noviembre de 2021; 148(5).\n15. Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. American journal of obstetrics and gynecology. 26 de marzo de 2021.\n16. Kharbanda EO, Haapala J, DeSilva M, Vazquez-Benitez G, Vesco KK, Naleway AL, et al. Spontaneous Abortion Following COVID-19 Vaccination During Pregnancy. Jama. 26 de octubre de 2021; 326(16):1629-31.\n17. Magnus MC, Gjessing HK, Eide HN, Wilcox AJ, Fell DB, Haberg SE. Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage. The New England journal of medicine. 20 de octubre de 2021.\n18. Trostle ME, Limaye MA, Avtushka V, Lighter JL, Penfield CA, Roman AS. COVID-19 vaccination in pregnancy: early experience from a single institution. Am J Obstet Gynecol MFM. 16 de agosto de 2021; 3(6):100464.  \n19. Trostle ME, Penfield CA, Roman AS. Adjustment of the spontaneous abortion rate following COVID-19 vaccination. Am J Obstet Gynecol MFM. 14 de octubre de 2021: 100511.  \n20. Zauche LH, Wallace B, Smoots AN, Olson CK, Oduyebo T, Kim SY, et al. Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion. The New England journal of medicine. 14 de octubre de 2021; 385(16):1533-5.\n21. Schaler L, Wingfield M. COVID-19 vaccine - can it affect fertility? Ir J Med Sci. 15 de octubre de 2021. https://www.ncbi.nlm.nih.gov/pubmed/34496196.\n22. Bowman CJ, Bouressam M, Campion SN, Cappon GD, Catlin NR, Cutler MW, et al. Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine. Reprod Toxicol. Agosto de 2021; 103:28-35.\n23. Bentov Y, Beharier O, Moav-Zafrir A, Kabessa M, Godin M, Greenfield CS, et al. Ovarian follicular function is not altered by SARS-CoV-2 infection or BNT162b2 mRNA COVID-19 vaccination. Hum Reprod. 18 de agosto de 2021; 36(9):2506-13.\n24. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. The New England journal of medicine. 17 de junio de 2021; 384(24):2273-82.\n25. Centros para la Prevenci\u00f3n y el Control de Enfermedades. v-safe and Registry Monitoring people who report pregnancy. 2021, consultado el 1 de julio de 2021; disponible en: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafepregnancyregistry.html\u2777\n\u2779\nHigh-risk pregnancy experts\n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}